0001209191-20-006298.txt : 20200204
0001209191-20-006298.hdr.sgml : 20200204
20200204161533
ACCESSION NUMBER: 0001209191-20-006298
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200131
FILED AS OF DATE: 20200204
DATE AS OF CHANGE: 20200204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SACHS BRUCE I
CENTRAL INDEX KEY: 0001197036
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20573865
MAIL ADDRESS:
STREET 1: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-31
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001197036
SACHS BRUCE I
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
0
0
0
Common Stock
2020-01-31
4
M
0
20000
53.85
A
31210
D
Common Stock
2020-01-31
4
S
0
1700
224.02
D
29510
D
Common Stock
2020-01-31
4
S
0
1858
224.98
D
27652
D
Common Stock
2020-01-31
4
S
0
4198
226.32
D
23454
D
Common Stock
2020-01-31
4
S
0
5644
227.01
D
17810
D
Common Stock
2020-01-31
4
S
0
300
227.66
D
17510
D
Common Stock
2020-01-31
4
S
0
600
228.33
D
16910
D
Common Stock
2020-01-31
4
S
0
500
229.90
D
16410
D
Common Stock
2020-01-31
4
S
0
1200
230.87
D
15210
D
Common Stock
2020-01-31
4
S
0
1200
232.04
D
14010
D
Common Stock
2020-01-31
4
S
0
1800
233.13
D
12210
D
Common Stock
2020-01-31
4
S
0
900
234.15
D
11310
D
Common Stock
2020-01-31
4
S
0
100
235.40
D
11210
D
Stock Option (Right to Buy)
53.85
2020-01-31
4
M
0
20000
0.00
D
2021-05-31
Common Stock
20000
0
D
Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $224.02 (range $223.58 to $224.40).
Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $224.98 (range $224.66 to $225.21).
Open market sales reported on this line occurred at a weighted average price of $226.32 (range $225.62 to $226.60).
Open market sales reported on this line occurred at a weighted average price of $227.01 (range $226.70 to $227.59).
Open market sales reported on this line occurred at a weighted average price of $227.66 (range $227.62 to $227.70).
Open market sales reported on this line occurred at a weighted average price of $228.33 (range $227.97 to $228.78).
Open market sales reported on this line occurred at a weighted average price of $229.90 (range $229.16 to $230.12).
Open market sales reported on this line occurred at a weighted average price of $230.87 (range $230.32 to $231.23).
Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.45 to $232.42).
Open market sales reported on this line occurred at a weighted average price of $233.13 (range $232.69 to $233.49).
Open market sales reported on this line occurred at a weighted average price of $234.15 (range $233.77 to $234.66).
Fully vested.
/s/ Omar White, Attorney-in-Fact
2020-02-04